Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) treatment remains challenging. CD70 was reported as a promising AML-specific antigen. Preclinically, CAR T-cell with single-chain-variable fragment (scFv) or truncated CD27 targeting CD70 has been reported to treat AML. However, various disadvantages includin...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jiali, Ge, Tong, Zhu, Xiaojian, Wang, Jue, Zeng, Yuhao, Mu, Wei, Cai, Haodong, Dai, Zhenyu, Jin, Jin, Yang, Yongkun, Hu, Guang, Mao, Xia, Zhou, Jianfeng, Zhu, Li, Huang, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264288/
https://www.ncbi.nlm.nih.gov/pubmed/36932256
http://dx.doi.org/10.1007/s00262-023-03422-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264288/
https://www.ncbi.nlm.nih.gov/pubmed/36932256
http://dx.doi.org/10.1007/s00262-023-03422-6

Ejemplares similares